About: ABT-436

An Entity of Type: chemical substance, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

ABT-436 is an orally active, highly selective vasopressin V1B receptor antagonist which was under development by Abbott Laboratories and AbbVie for the treatment of major depressive disorder, anxiety disorders, and alcoholism but was discontinued. It reached phase II clinical trials prior to the discontinuation of its development.

Property Value
dbo:abstract
  • ABT-436 is an orally active, highly selective vasopressin V1B receptor antagonist which was under development by Abbott Laboratories and AbbVie for the treatment of major depressive disorder, anxiety disorders, and alcoholism but was discontinued. It reached phase II clinical trials prior to the discontinuation of its development. (en)
dbo:casNumber
  • 1642328-87-7
dbo:fdaUniiCode
  • U6SIR21GRB
dbo:wikiPageID
  • 54283761 (xsd:integer)
dbo:wikiPageLength
  • 3449 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1081386427 (xsd:integer)
dbo:wikiPageWikiLink
dbp:casNumber
  • 1642328 (xsd:integer)
dbp:routesOfAdministration
dbp:unii
  • U6SIR21GRB (en)
dbp:wikiPageUsesTemplate
dct:subject
rdf:type
rdfs:comment
  • ABT-436 is an orally active, highly selective vasopressin V1B receptor antagonist which was under development by Abbott Laboratories and AbbVie for the treatment of major depressive disorder, anxiety disorders, and alcoholism but was discontinued. It reached phase II clinical trials prior to the discontinuation of its development. (en)
rdfs:label
  • ABT-436 (en)
owl:sameAs
prov:wasDerivedFrom
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License
  NODES
admin 3